PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Journal: Science Translational Medicine

Published: 2018-07-18

DOI: 10.1126/scitranslmed.aaq1093

Affiliations: 8

Authors: 18

Go to article
Institutions FC
Turku Centre for Biotechnology (CBT), Finland 0.38
Institute for Molecular Medicine Finland (FIMM), Finland 0.22
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.17
Case Comprehensive Cancer Center (Case CCC), CWRU, United States of America (USA) 0.11
Department of Mathematics and Statistics, UTU, Finland 0.06
Institute of Biomedicine, UTU, Finland 0.04
Turku Doctoral Programme of Molecular Medicine (TuDMM), UTU, Finland 0.01
Turku Doctoral Programme of Biomedical Sciences (TuBS), UTU, Finland 0.01